SB-277011 GlaxoSmithKline - PubMed (original) (raw)
Affiliations
- PMID: 11757796
Review
SB-277011 GlaxoSmithKline
G Remington et al. Curr Opin Investig Drugs. 2001 Jul.
Abstract
It is presumed that GlaxoSmithKline has taken over from SmithKline Beecham in investigating the highly selective dopamine D3 antagonist SB-277011 and its analogs for the potential treatment of schizophrenia [284490] following the merger of Glaxo Wellcome and SmithKline Beecham in December 2000 [394715]. In June 2000, it was reported that novel 2,3,4,5-tetrahydro-1H-benzazepines and 2,3-dihydro-1H-isoindoles, including SB-277011, had shown high affinity and selectivity for the dopamine D3 receptor. All compounds were suggested to have further potential roles in the treatment of drug abuse and psychosis [372205]. In November 2000, data presented at the 30th Neuroscience meeting in New Orleans, LA, demonstrated that D3 receptor blockade with SB-277011 specifically altered neurochemical effects in the nucleus accumbens without the non-selective effects, such as catalepsy, seen with some other antagonists [390460].
Similar articles
- Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AK, Hagan JJ. Reavill C, et al. J Pharmacol Exp Ther. 2000 Sep;294(3):1154-65. J Pharmacol Exp Ther. 2000. PMID: 10945872 - Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B. Schoemaker H, et al. J Pharmacol Exp Ther. 1997 Jan;280(1):83-97. J Pharmacol Exp Ther. 1997. PMID: 8996185 - [Functional role of dopamine D3 receptor in schizophrenia].
Semba J. Semba J. Nihon Shinkei Seishin Yakurigaku Zasshi. 2004 Feb;24(1):3-11. Nihon Shinkei Seishin Yakurigaku Zasshi. 2004. PMID: 15027325 Review. Japanese. - Dopamine D3 receptor ligands with antagonist properties.
Hackling AE, Stark H. Hackling AE, et al. Chembiochem. 2002 Oct 4;3(10):946-61. doi: 10.1002/1439-7633(20021004)3:10<946::AID-CBIC946>3.0.CO;2-5. Chembiochem. 2002. PMID: 12362359 Review.
Cited by
- Low-dose polypharmacology targeting dopamine D1 and D3 receptors reduces cue-induced relapse to heroin seeking in rats.
Ewing ST, Dorcely C, Maidi R, Paker G, Schelbaum E, Ranaldi R. Ewing ST, et al. Addict Biol. 2021 Jul;26(4):e12988. doi: 10.1111/adb.12988. Epub 2021 Jan 25. Addict Biol. 2021. PMID: 33496050 Free PMC article. - New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders.
Newman AH, Ku T, Jordan CJ, Bonifazi A, Xi ZX. Newman AH, et al. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:609-628. doi: 10.1146/annurev-pharmtox-030220-124205. Annu Rev Pharmacol Toxicol. 2021. PMID: 33411583 Free PMC article. - PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats.
Higley AE, Spiller K, Grundt P, Newman AH, Kiefer SW, Xi ZX, Gardner EL. Higley AE, et al. J Psychopharmacol. 2011 Feb;25(2):263-73. doi: 10.1177/0269881109358201. Epub 2010 Feb 8. J Psychopharmacol. 2011. PMID: 20142301 Free PMC article. - Mechanism-based medication development for the treatment of nicotine dependence.
Xi ZX, Spiller K, Gardner EL. Xi ZX, et al. Acta Pharmacol Sin. 2009 Jun;30(6):723-39. doi: 10.1038/aps.2009.46. Epub 2009 May 11. Acta Pharmacol Sin. 2009. PMID: 19434058 Free PMC article. Review. - Hypothesis-driven medication discovery for the treatment of psychostimulant addiction.
Xi ZX, Gardner EL. Xi ZX, et al. Curr Drug Abuse Rev. 2008 Nov;1(3):303-27. doi: 10.2174/1874473710801030303. Curr Drug Abuse Rev. 2008. PMID: 19430578 Free PMC article. Review.